RYE, N.Y., Sept. 21 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, presented at the Rodman & Renshaw Annual Global Investment Conference held September 12-15 in New York City. The global investment conference attracted more than 5,000 investors and other attendees.
"Curemark was one of only a handful of private companies invited to present at the conference, which included a full roster of 610 companies presenting," said Dr. Joan Fallon said, Curemark founder and CEO. "To be able to participate was a terrific opportunity to showcase our progress, as the event was essentially a packed house."
At the conference, Fallon discussed the momentum of Curemark's drug pipeline. CM-AT, the company's autism treatment in development, is currently in Phase III clinical trials at 13 sites nationwide and has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). The FDA also has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial to study the use of the company's compound CM-4612 in the treatment of attention deficit hyperactivity disorder (ADHD).
Curemark's autism treatment targets enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function. If approved, it will be one of the first therapies to address the underlying physiology of autism.
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
|SOURCE Curemark, LLC|
Copyright©2010 PR Newswire.
All rights reserved